SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: January 23, 2003
QLT Inc.
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ --------- -------------------------
(Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
-------------------------------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
ITEM 5. OTHER EVENTS
On January 23, 2003, QLT Inc. reported that its alliance partner,
Novartis, announced global Visudyne(R) (verteporfin) sales of
approximately US$77.0 million (CAD$120.9 million) for the quarter and
US$287.1 million (CAD$450.6 million) for the year ended December 31,
2002. Visudyne sales for the fourth quarter and the full year were
ahead of analysts' consensus estimates and represent increases of 25%
and 29% over sales in the fourth quarter and annual sales in 2001
respectively.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------ -----------
99.1 Press release dated January 23, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
------------
(Registrant)
Date January 23, 2003 By /s/ Paul J. Hastings
------------------- ------------------------------------
(Signature)
Paul J. Hastings
President and Chief Executive Officer